Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

20051,515 citationsJournal Articlebronze Open Access

Authors

George Lau · University of Hong Kong

Teerha Piratvisuth · Songklanagarind Hospital

Kang Luo · Nanfang Hospital

Patrick Marcellin · Inserm

Satawat Thongsawat · Chiang Mai University

Graham Cooksley · Royal Brisbane and Women's Hospital

Edward Gane ·

Abstract

In patients with HBeAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg seroconversion.

Topics & Keywords

Hepatitis B Virus Studies Hepatitis C virus research Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 26, pp. 2682-2695

DOI: 10.1056/nejmoa043470

Field-Weighted Citation Impact: 76.98